Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | HTR4 | Q13639 | 7/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21055572 | 1.00 | DRD2 (0.53) | DRD2ADRA2BADRA2CDRD3HTR2B | |
| SCHEMBL21054909 | 1.00 | DRD2 (0.53) | DRD2ADRA2BADRA2CDRD3HTR2B | |
| SCHEMBL7372752 | 0.94 | LMNA (0.47) | DRD2ADRA2BADRA2CDRD3HTR2B | |
| SCHEMBL7381604 | 0.93 | DRD2 (0.44) | DRD2ADRA2BADRA2CDRD3HTR2B | |
| SCHEMBL10559503 | 0.92 | DRD2 (0.53) | DRD2ADRA2BADRA2CDRD3HTR2B | |
| SCHEMBL10559935 | 0.91 | DRD2 (0.52) | DRD2ADRA2BADRA2CDRD3HTR2B | |
| SCHEMBL10564984 | 0.91 | DRD2 (0.52) | DRD2ADRA2BADRA2CDRD3HTR2B | |
| SCHEMBL7380370 | 0.90 | DRD2 (0.55) | DRD2ADRA2BADRA2CDRD3HTR2B | |
| SCHEMBL10561934 | 0.90 | DRD2 (0.49) | DRD2ADRA2BADRA2CDRD3HTR2B | |
| SCHEMBL10563605 | 0.90 | DRD2 (0.51) | DRD2ADRA2BADRA2CDRD3HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112236138-B | Crystal forms and methods of making the same | 赛诺维信制药公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-3720435-B1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11767293-B2 | Crystal forms and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230072389-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2023-03-09 | — | — | US | disclosed |
| US-11370753-B2 | Crystal forms and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210061759-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2021-03-04 | — | — | US | disclosed |
| CN-112236138-A | Crystalline forms and methods of making the same | 赛诺维信制药公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-3720435-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10800738-B2 | Crystal forms and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200165200-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190315686-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-10-17 | — | — | US | disclosed |
| US-10377708-B2 | Crystal forms and production methods thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-08-13 | — | — | US | disclosed |
| WO-2019113084-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190169123-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-06-06 | — | — | US | disclosed |
| US-20100105755-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF DOPAMINE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-6187807-B1 | ADMINISTERING (S)(-)-AMISULPRIDE OR SALT THEREOF FREE OF THE (R)-(+)-STEREOISOMER, TO ELICIT ANTIPSYCHOTIC PROPERTIES IN A PATIENT | SANOFI-SYNTHELABO (FR) | 2001-02-13 | — | — | US | disclosed |
| US-6169094-B1 | ANTIPSYCHOTIC AGENTS | SANOFI-SYNTHELABO (FR) | 2001-01-02 | — | — | US | disclosed |
| EP-0177654-A1 | Synergistic contraceptive mixture | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1986-04-16 | — | — | EP | disclosed |
| US-4401822-A | ANISEROTONINE AGENTS; APOMORPHINE ANTAGONIST | SOCIETE DE'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE FRANCE (FR) | 1983-08-30 | — | — | US | disclosed |
| US-4294828-A | ANTIEMETIC AND ANTISEROTONIN | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE DE-FRANCE (FR) | 1981-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800738-B2 | Crystal forms and production methods thereof | CYP4F3, HMGCR, LSS | DRD2 752/4885ADRA2B 474/4885ADRA2C 212/4885 |
| US-11767293-B2 | Crystal forms and production methods thereof | CYP4F3, HMGCR, LSS | DRD2 752/4885ADRA2B 474/4885ADRA2C 212/4885 |
| US-20230072389-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | CYP4F3, HMGCR, LSS | DRD2 752/4885ADRA2B 474/4885ADRA2C 212/4885 |
| US-20200165200-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | CYP4F3, HMGCR, LSS | DRD2 752/4885ADRA2B 474/4885ADRA2C 212/4885 |
| US-20210061759-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | CYP4F3, HMGCR, LSS | DRD2 752/4885ADRA2B 474/4885ADRA2C 212/4885 |
| US-20190169123-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | CYP4F3, HMGCR, LSS | DRD2 752/4885ADRA2B 474/4885ADRA2C 212/4885 |
| US-20190315686-A1 | CRYSTAL FORMS AND PRODUCTION METHODS THEREOF | CYP4F3, HMGCR, LSS | DRD2 752/4885ADRA2B 474/4885ADRA2C 212/4885 |
| US-20100105755-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF DOPAMINE RECEPTOR | DBH, SLC6A3, HTR5A | DRD2 44/4885ADRA2B 22/4885ADRA2C 17/4885 |
| US-11370753-B2 | Crystal forms and production methods thereof | CYP4F3, HMGCR, LSS | DRD2 752/4885ADRA2B 474/4885ADRA2C 212/4885 |
| US-10377708-B2 | Crystal forms and production methods thereof | CYP4F3, HMGCR, LSS | DRD2 752/4885ADRA2B 474/4885ADRA2C 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.